Skip to content
OCUT-2C
Tissue
Pleura
Disease
Anaplastic thyroid carcinoma
Metastatic site
Pleural effusion
Synonyms
Ocut-2C, OCUT2C, Osaka City University Thyroid-2C

Documents

OCUT-2C

Cell line · Product number 305544

OCUT-2C (Osaka City University Thyroid-2C) is a human anaplastic thyroid carcinoma cell line established from a pleural effusion of an 81-year-old Japanes...

US$700.00excl. tax and shipping
In stock
Lot
Recommended (freshest lot)
  • CoA
1

01General information

Description

OCUT-2C (Osaka City University Thyroid-2C) is a human anaplastic thyroid carcinoma cell line established from a pleural effusion of an 81-year-old Japanese female patient. The line grows as an adherent monolayer. OCUT-2C harbors two clinically significant oncogenic mutations: BRAF p.Val600Glu (V600E) and PIK3CA p.His1047Arg (H1047R), reflecting the concurrent MAPK and PI3K/Akt pathway activation commonly observed in dedifferentiated and anaplastic thyroid carcinomas. The presence of both BRAF V600E and PIK3CA H1047R provides a clinically relevant model for studying resistance mechanisms and combination therapy strategies in anaplastic thyroid cancer.

OCUT-2C is applicable in studies of anaplastic thyroid carcinoma biology, BRAF V600E + PI3K H1047R co-mutation biology, MAPK/ERK and PI3K/Akt pathway signalling, targeted therapy evaluation (BRAF inhibitors, MEK inhibitors, PI3K/mTOR inhibitors), and combination therapy approaches. As an anaplastic thyroid carcinoma model from a Japanese patient, it is relevant for studying the aggressive, treatment-resistant biology characteristic of this malignancy with a very poor prognosis.

Tissue
Pleura
Disease
Anaplastic thyroid carcinoma
Metastatic site
Pleural effusion
Applications
Anaplastic thyroid carcinoma research; BRAF V600E + PIK3CA H1047R co-mutation biology; MAPK/PI3K pathway signalling; BRAF/MEK inhibitor evaluation; PI3K/mTOR inhibitor evaluation; combination therapy strategies; thyroid cancer drug resistance
Synonyms
  • Ocut-2C
  • OCUT2C
  • Osaka City University Thyroid-2C

02Classification

Organism
Human
Sex
Female
Growth properties
Adherent
GMO status
Non-GMO
GMO status details
No genetic modification; wildtype anaplastic thyroid carcinoma cell line with somatic BRAF V600E and PIK3CA H1047R mutations
Biosafety level
1

03Characteristics

Morphology
Epithelial-like
Cell type
Epithelial cells
Doubling time
approx. 24 to 48 hours

04Identifiers

Citation
OCUT-2C (Cytion catalog number 305544)
NCBI TaxID
9606
Cellosaurus
CVCL_W915

05Expression and susceptibility

Mutational profile
Mutation: p.Val600Glu, Unspecified; Mutation: p.His1047Arg, Unspecified

06Handling and culture

Culture medium
RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a)
Incubation atmosphere

37°C, 5% CO2, humidified atmosphere.

Supplements
Supplement the medium with 10% FBS
Dissociation reagent
Accutase
Subculturing
Remove medium, wash with PBS without calcium and magnesium, cover with Accutase, incubate 8–10 min at RT, resuspend in medium, centrifuge 300×g 3 min, discard supernatant, reseed in fresh medium.
Split ratio
1 to 5
Seeding density
1 to 3 × 10⁴ cells/cm²
Fluid renewal
Every 2 to 3 days
Thawing and culturing
  1. Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit.

  2. Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required.

  3. For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains.

  4. Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening.

  5. Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently.

  6. Centrifuge the mixture at 200 x g for 5 minutes, carefully discard the supernatant containing freezing medium.

  7. Follow the procedure described under Post-Thaw Recovery

07Quality control and cryopreservation

Freeze medium
As a cryopreservation medium, we use complete growth medium + 10% DMSO for adequate post-thaw viability.
Storage conditions

For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen.

Shipping conditions

Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage.

08Donor

Donor age
81Y
Ethnicity
Japanese